Investor Presentaiton slide image

Investor Presentaiton

State-of-the-art Manufacturing Facilities Designed to, Built with, and Operating at International Standards R&D Labs Total capacity in the future: 60,000 L 36,000L Warehouse 24,000L QC labs Innovent Administration Innovent Manufacturing facilities (a total of 24,000L capacity) received cGMP certification from the NMPA, providing competitive advantage on the production cost of our products. Additional 36,000L capacity expected to complete construction and validation in 2021 Facilities were designed to meet FDA, EMA, PMDA and NMPA standards, and support the full process from DS to DP. DS, DP and GMP were successfully audited Facilities have undergone ordinary course, comprehensive annual audits to evaluate compliance with industry cGMP and quality compliance standards Manufacturing team has extensive experience at multi-national bio-pharmaceutical companies Confidential Copyright©2021 Innovent Biologics 11 Innovent
View entire presentation